Bluebird Bio Gets FDA OK of Lyfgenia Gene Therapy in Sickle-Cell Disease
09 12월 2023 - 2:03AM
Dow Jones News
By Colin Kellaher
Bluebird bio has won U.S. Food and Drug Administration approval
of its Lyfgenia gene therapy for sickle-cell disease, making it one
the first two cell-based gene therapies to win a U.S. green light
for the inherited blood disorder.
The FDA on Friday said the approval covers Lyfgenia for the
treatment of patients 12 years of age and older with sickle-cell
disease and a history of vaso-occlusive events.
The FDA nod, nearly two weeks ahead of the target action date of
Dec. 20, comes on the same day the agency cleared the Casgevy
gene-therapy from CRISPR Therapeutics and Vertex Pharmaceuticals,
marking the first U.S. approval for a drug using the gene-editing
technology known as Crispr.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 08, 2023 11:48 ET (16:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
bluebird bio (NASDAQ:BLUE)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
bluebird bio (NASDAQ:BLUE)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
